Rena Buckstein

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype

Daniel T. Starczynowski, Florian Kuchenbauer, Bob Argiropoulos et al. · Nature Medicine · 2009 · 650 citations

Life Sciences, Molecular Biology, Molecular Genetics +12

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 537 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

Michael Crump, John Kuruvilla, Stephen Couban et al. · Journal of Clinical Oncology · 2014 · 463 citations · Full text

Medicine, Oncology, Pharmacology +14

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Thomas E. Witzig, Julie M. Vose, Pier Luigi Zinzani et al. · Annals of Oncology · 2011 · 393 citations · Full text

Medicine, Oncology, Pharmacology +13